Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Authors :: Carrie Aldrich
Tara Elisabeth Seery
Andrea J. Bullock
Dimitrios Chondros
W. Wu
Mark M. Zalupski
Darren Sigal
Fadi Braiteh
Ping Jiang
Paul S. Ritch
Sunil R. Hingorani
Andrew Eugene Hendifar
Lei Zheng
Jie Pu
William P. Harris
Sihem Khelifa
Nathan Bahary
Source :: Annals of Oncology. 28:v261
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Pancreatic ductal adenocarcinoma
business.industry
Phases of clinical research
Hematology
Gemcitabine
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
030211 gastroenterology & hepatology
In patient
business
medicine.drug
Nab-paclitaxel

Full Text Access

Tools